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Cigarette smoking is the major cause of lung cancer (Doll,
1984; Loeb et al., 1984). Although the early events in lung
tumorigenesis have still to be identified, it has been shown
that cigarette smoking is associated with an increase in levels
of serum alkaline phosphatase (Maslow et al., 1983; Tonik et
al., 1983) which was subsequently shown to be due to
a placental-like form (PLAP-like AP) of the enzyme
(McLaughlin et al., 1984; Tucker et al., 1985a, b). The major
source of the enzyme in cigarette smokers is probably the
lung (Williams et al., 1986).
In this study we have explored the quantitative relation-
ship between the amount of cigarette smoke inhaled each
day and elevations in serum PLAP-like AP levels in an
attempt to relate possible early tumorigenic events with
tobacco consumption. Estimated smoke intake was based not
only on numbers of cigarettes reported to be smoked each
day, but also on objective estimates of nicotine intake
obtained by determining nicotine metabolite levels in blood
and urine since nicotine is a specific component of the
particular phase of tobacco smoke and because the tar and
nicotine yields of most cigarettes are very highly correlated
(Russell, 1976).
As part of an ongoing prospective study, coded serum and
urine samples were obtained between 1977 and 1980 from
over 2,000 normal women aged 35 years or more, living in
Guernsey (Bulbrook et al., 1986). One to two weeks after a
24-hour urine sample had been collected, blood samples were
taken between 1300 and 1900 hours and a detailed health
questionnaire was completed. A smoking history was also
obtained from the first 1,200 volunteers. Aliquots of urine
and sera were then stored at -20°C until analysis.
PLAP-like AP levels were measured in 753 of the serum
samples using the method of Tucker et al. (1985b), in which
a monoclonal antibody (HI7E2) was absorbed onto micro-
titre plate wells, serum aliquots added and the activity of the
bound enzyme estimated colorimetrically using dinitrophenol
phosphate as substrate and measuring the final optical
density at 405 nm using a Titertek Multiscan instrument.
An estimate of the relative amount of nicotine inhaled
each day was obtained either from the urinary excretion of
nicotine and its metabolites, after allowing for the influence
of diuresis, or by measuring the concentration of nicotine's
major serum metabolite, cotinine. The nicotine metabolite/
creatinine (NM/C) ratios (as ,ug apparent cotinine per mg
creatinine) of the 955 urine samples available for analysis
from the first 2,000 volunteers were determined colorimetri-
cally using the barbituric acid and alkaline picrate methods
described previously (Peach et al., 1985). The actual smoking
status of these 955 subjects was biochemically proven by
testing aliquots of urine for nicotine metabolites by the
specific qualitative diethylthiobarbituric acid extraction
method (Peach et al., 1985) since the only source of nicotine
intake is by smoking tobacco or taking snuff. Among the
2,000 volunteers, smoking histories had been elicited from
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1,100 and estimates of PLAP-like AP were made on serum
samples from 663. Cotinine concentrations (ngml-1) were
estimated in 165 serum samples by a minor modification of
the radioimmunoassay method of Knight et al. (1985) in
which the bound 1125-label was precipitated using polyethy-
lene glycol and sheep anti-rabbit immunoglobulin.
The results of these studies showed that there was a
progressive increase in mean serum PLAP-like AP levels,
urinary nicotine metabolite excretion (expressed as NM/C
ratios), and serum cotinine levels with increasing self-
reported cigarette consumption (Table I). Thus there were
highly significant and positive correlations between any two
of these four variables (Table II). Similar correlations were
demonstrated for biochemically proven smokers. These were
also significant correlations between serum PLAP-like AP
levels and both urinary nicotine metabolite excretion and
serum cotinine levels among women reported to be smoking
either 1-10 or 11-20 cigarettes per day (Table I).
The results presented in Table I show that there was a
marked tendency for the urinary NM/C ratios and serum
cotinine concentrations to plateau out with increasing
numbers of cigarettes reported to have been smoked. This
accords with previous evidence concerning the reduced
efficiency with which cigarettes are smoked when daily
consumption is very high (Feyerabend et al., 1982; Peach et
al., 1985).
There was a strikingly high correlation (r=0.83) between
the urinary NM/C ratios and serum cotinine levels of the 55
proven smokers in whom both estimations were made. Since
the inherent errors of the urinary and serum methods are
essentially independent, it was concluded that each method
must provide a reliable estimate of the relative daily intake
of nicotine by smokers.
Since the tar/nicotine ratios of most brands of cigarettes
are very similar, both measures of nicotine intake should
provide good evidence of the relative rates at which cigarette-
derived carcinogens were being trapped in the lungs of
different smokers, although there might be substantial indivi-
dual differences in the extent to which carcinogens were
activated by hepatic metabolism (Idle et al., 1981).
The marked individual differences in the amounts of
nicotine inhaled by smokers in each of the three self-
reporting categories (Table I) is in accordance with previous
evidence for differences in the efficiency with which cigar-
ettes are smoked (Feyerabend et al., 1982; Peach et al.,
1985), as well as inadvertent or deliberate errors of recall
regarding cigarette consumption (Sillet et al., 1978; Peach et
al., 1986). Thus in the current study 14 (3%) of the 475
volunteers who denied smoking were unequivocally identified
as smokers by the diethylthiobarbituric acid method, and
had NM/C ratios averaging 7.6 which was only slightly less
than the mean for the self-admitted smokers (8.4). Since
many of the adverse effects of smoking are markedly dose-
dependent (Butler et al., 1972; Doll & Peto, 1978; Doll et al.,
1980; Loeb et al., 1984; Hirayama, 1987), these findings
emphasise the importance of using objective measurements
of nicotine intake (Haddow et al., 1987) in epidemiological
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Table I Correlations between serum PLAP-like AP levels and smoke intake
Reported daily cigarette consumption
0 1-10 11-20 >20
PLAP-like AP'
Meanb 0.20 0.40 0.63 0.77
(Range ±1 s.d.) (0.14-0.27) (0.17-0.81) (0.31-1.35) (0.40-1.64)
Median 0.19 0.35 0.64 1.0
(Range; NC) (0.08-2.009; 485) (0.10-2.00; 66) (0.12-2.00; 70) (0.17-2.00; 42)
Urinary NM/Cd
Meanb 0.86 3.76 11.3 12.0
(Range ±1 s.d.) (0.48-1.31) (1.27-8.43) (5.5-20.0) (6.7-19.4)
Median 0.10 3.72 12.7 11.9
(Range; N) (0.1-27.5; 475) (0.8-13.9; 47) (0.8-27.4; 46) (0.8-25.8; 24)
Serum contininee
Meanb <5h 25 108 127
(Range +1 s.d.) (6-100) (45-233) (62-260)
Median <5 29 117 163
(Range; N) (All <5; 43) (11-276; 32) (7-435; 51) (13-362; 34)
Correlations
PLAP-like AP vs.
urinary NM/C
Rf - 0.47 0.48 0.40
N 40 44 20
P <0.01 <0.001 NS (<0.10)
PLAP-like AP vs.
serum cotinine
R 0.43 0.45 0.28
N 32 51 34
P <0.05 <0.001 NS (>0.10)
aOptical density units; for conversion to International Units, see Tucker et al. (1985b); bGeometric mean;
CNumber of observations; dUrinary nicotine metabolites/creatinine (ygmg-1); eSerum cotinine (ngml-1);
'Linear correlation coefficient; g2.00 is the upper limit of the assay. There were 1, 3, 4 and 3 sera with such
values within the smoking categories 0, 1-10, 11-20 and >20 cigs/day, respectively; hLower limit of
sensitivity.
Table II Correlations between serum PLAP-like AP levels and nicotine intake in self-reported smokers
Serum PLAP Serum cotinine Urinary
(optical density units) (ngml-1) nicotine metabolite ratio
Cigarette consumptionb 0.32 (178)' 0.56 (117) 0.51 (117)
Serum PLAP-like AP
(optical density units) 0.49 (117) 0.50 (104)
Serum cotinine (ngml-1) 0.82 (54)
aExpressed as correlation coefficient (number); bIn calculating the correlation coefficients cigarette
consumption of 1-10, 11-20 and >20 cigarettes/day have been taken as an average of 5, 15 and 25
cigarettes/day, respectively. All correlations were significant at P<0.001.
studies of smoking. In view of the convenience of collecting
urine samples and the simplicity of the colorimetric methods
for the estimation of nicotine metabolites/creatinine ratios,
the urinary method would appear to be ideal for such a
purpose, especially if automated modifications for their assay
are employed (Barlow et al., 1987; Puhakainen et al., 1988).
It is probable that PLAP-like AP elevations are due to tar,
or other smoke components, rather than to nicotine since we
have observed that in nine smokers who were switched to
chewing nicotine-impregnated gum, serum PLAP-like AP fell,
after 2 months, to levels approaching those of non-smokers.
The potential value of using PLAP-like AP estimations as a
'marker' for tar intake should therefore be explored,
especially in investigations as to whether nicotine-enhanced
cigarettes might be less hazardous than standard brands
(Russell, 1976; Holland et al., 1986).
The authors are indebted to the ladies of Guernsey for volunteering
to participate in the prospective study. R.D. Barlow and R.B. Stone
are also grateful for support from the Tobacco Products Research
Trust.
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